Vinorelbine and 5-fluorouracil bolus and/or continuous venous infusion plus levofolinic acid as second-line chemotherapy for metastatic breast cancer: An analysis of results in clinical practice of the Gruppo Oncologico Italie Meridionale (GOIM)

Anticancer Research

Volumn 26, Issue 4 B, 2006, Pages 3143-3150

  Gebbia, Vittorio ^a,b   Caruso, Michele ^c   Borsellino, Nicolò ^d   Ajello, Rosanna ^c   Tirrito, Maria Lina ^e   Chiarenza, Maurizio ^f   Valenza, Roberto ^f   Verderame, Francesco ^g   Varvara, Francesca ^h   Marrazzo, Antonio ^a,b   Bajardi, Eugenia ^b   Ferraù, Francesco ⁱ   Bordonaro, Roberto ^j   Tralongo, Paolo ^k  

^a UNIVERSITY OF PALERMO   (Italy)

^b LA MADDALENA CANCER CENTER   (Italy)

^c Centro Catanese di Oncologia   (Italy)

^d Buccheri La Ferla Hospital   (Italy)

^e Medical Oncology Unit   (Italy)

^f Osp Vittorio Emanuele III   (Italy)

^g Ospedale Civile   (Italy)

^h Casa di Cura Villa dei Gerani   (Italy)

ⁱ Ospedale San Vincenzo   (Italy)

^j UNIVERSITY OF CATANIA   (Italy)

^k Ospedale De Maria   (Italy)

more..

Author keywords

Breast cancer; Metastases; Second line chemotherapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; NAVELBINE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BONE METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; NEURITIS; NEUTROPENIA; PARESTHESIA; PRIMARY HEALTH CARE; PRIORITY JOURNAL; SOFT TISSUE METASTASIS; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH; VISCERAL METASTASIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LEUCOVORIN; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; STEREOISOMERISM; VINBLASTINE;

EID: 33746727064     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Harris JR, Morrow M and Bonadonna G: Cancer of the breast. In: Cancer. Principles and Practice of Oncology, Fourth edition. De Vita VT Jr, Hellman S, Rosenberg SA (eds.). Philadelphia, PA: Lippincott Company, pp. 1264-1332, 1993.
2. Sledge GW: Breast cancer as a world challenge. Clin Breast Cancer 5: 11, 2004.
3. Early Breast Cancer Trialist's Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1-15, 1992.
4. Sledge GW: First-line chemotherapy for advanced breast cancer. Cancer Control 6(Suppl 2): 17-21, 1999.
5. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Besehenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Riva A and Aapro M: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17: 1413-1424, 1999.
6. Cardoso F, Di Leo A, Lohrisch C, Bernard C, Ferreira F and Piccart MJ: Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 13: 197-207, 2002.
7. O'Brien MER, Leonard RC, Barrett-Lee PJ, Eggleton SPH and Bizzari JP: Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. Ann Oncol 10: 205-210, 1999.
8. Gebbia V and Puozzo C: Oral versus intravenous vinorelbine: clinical safety profile. Exp Opin Drug Safety 4: 915-928, 2005.
9. Degardin M, Bonneterre J, Hecquet B, Pion JM, Adenis A, Horner D and Demaille A: Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 5: 423-426, 1994.
10. Gasparini G, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi RB and Ambrosiani G: Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 12: 2094-2101, 1994.
11. Margolin KA, Doroshow JH, Akman SA et al: Effective initial therapy of advanced breast cancer with fluorouracil and high dose continuous infusion calcium leucovorin. J Clin Oncol 10: 1278-1283, 1992.
12. Swain SM, Lippman ME, Egan EF et al: Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 890-899, 1989.
13. Doroshow JH, Leong L, Margolin K et al: Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous-infusion leucovorin calcium. J Clin Oncol 7: 439-444, 1989.
14. Marini G, Simoncini E, Zaniboni A et al: 5-Fluorouracil and high-dose folinic acid as salvage treatment of advanced breast cancer: an update. Oncology 44: 336-340, 1987.
15. Gebbia V, Mauceri G, Testa A, Tirrito ML, Varvara F, Cucchiara A, Borsellino N, Girlando A, Ferrara M and Caruso F: Treatment of refractory metastatic breast cancer with 5-fluorouracil and levofolinic acid as 48 hours continuous venous infusion. Anticancer Res 19: 2289-2292, 1999.
16. Colucci G, Romito S, Gebbia V, Pacilio G, Giotta F, Testa A, Pezzella G, Durini E, Agostara B, Cariello S, Palazzo S and Gebbia N: Levofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM). Br J Cancer 72: 1245-1250, 1995.
17. Ray-Coquard I, Biron P, Bachelot T, Guastalla JP, Catimel G, Merrouche Y, Droz JP, Chauvin F and Blay JY: Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens. Cancer 82: 134-140, 1998.
18. Zambetti M, Demicheli R, De candis D, Antonelli G, Giacobone A, Terenziani M, Laffranchi A, Garbagnati F, Biasi S and Bonadonna G: Five-day infusion fluorouracil plus vinorelbine iv in metastatic pretreated breast cancer patients. Breast Cancer Res Treat 44: 255-260, 1997.
19. Froudarakis ME, Catimel G, Guastalla JP, Rebattu P and Clavel M: Phase II trial of navelbine and fluorouracil as second-line chemotherapy in metastatic breast carcinoma. Oncology 55: 87-88, 1998.
20. Kornek GV, Haider K, Kwasny W, Lang F, Krauss G, Hejna M, Radiz M, Weinlander G, Depisch D and Scheithauer W: Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and 1-leucovorin plus human granulocyte colony stimulating factor. Br J Cancer 78: 673-678, 1998.
21. Berruti A, Sperone P, Bottini A, Gorzegno G, Lorusso V, Brunelli A, Botta M, Tampellini M, Donadio M, Bancarella S, De lena M, Alquanti P and Dogliotti L: Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast carcinoma patients previously treated with anthracyclines. J Clin Oncol 18: 3370-3377, 2000.
22. Lombardi D, Magri MD, Crivellari D, Spazzapan S, Paolello C, De Cicco M, Di Lauro V, Scuderi C and Veronesi A: Combination chemotherapy with navelbine and continuous infusion of 5-fluorouracil in metastatic, chemotherapy refractory breast cancer. Ann Oncol 11: 1041-1043, 2000.
23. Zambelli A, Robustelli della Cuna FS, Ponchio L, Ucci G, da Prada O and Robustelli della Cuna G: Four-day infusion of fluorouracil plus vinorelbine as salvage treatment of heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 61: 241-247, 2000.
24. Zambetti M, Mariani G, Demicheli R, Verderio P, Potepan P and Garbagnati F: Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracycline and paclitaxel. Breast Cancer Res Treat 62: 135-139, 2000.
25. Pienkowski T and Jagiello-Gruszfeld A: Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines. Int J Clin Pharmacol Res 21: 111-117, 2001.
26. Boneterre J, Rochè H, Monnier A, Guastalla JP, Namer M, Fargeot P and Assadourian S: Docetaxel vs. 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 87: 1210-1215, 2002.
27. Razis E, Kosmidis P, Aravantinos G, Bakoyiannis C, Janinis J, Christodoulou C and Foutzilas G: Second line chemotherapy with 5-fluorouracil and vinorelbine in anthracycline and taxane pretreated patients with metastatic breast cancer. Cancer Invest 22:10-15, 2004.
28. Dieras V, Extra JM, Bellissant E, Espie M, Morvan F, Pierga JY, Mignot L, Tresca P and Marty M: Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. J Clin Oncol 14: 3097-3104, 1996.
29. Nolè F, deBraud F, Aapro M, Minchella I, De pas M, Zampino MG, Monti S, Androni G and Goldhirsch A: Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer : a regimen with a low subjective toxic burden. Ann Oncol 8: 865-870, 1997.
30. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
31. Hryniuk WM: Average relative dose intensity and the impact on design of clinical trials. Sem Oncol 14: 65-74, 1987.
32. Carlson RW: Quality of life issues in the treatment of metastatic breast cancer. Oncology 12(Suppl 4): 27-31, 1998.
33. ASCO: Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J Clin Oncol 14: 671-679, 1996.
34. Geels P, Eisenhaur E, Bezjak A et al: Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 18: 2395-2405, 2000.